Tempus AI announced a collaboration with the Institute for Follicular Lymphoma Innovation. The goal of the collaboration is to advance targeted therapy development for follicular lymphoma by ...

Tempus AI (NASDAQ:TEM) delivered a very mixed Q4 2024 earnings report that saw its shares sell off about 15% after hours. The main takeaway here is that Tempus' core business is expected to grow ...

Tempus AI (TEM) stock surged 13.4% on Thursday, hitting a new 52-week high of $86. The upside came after the health technology company announced a collaboration with the Institute for Follicular ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new collaboration with the Institute for Follicular ...